Core Viewpoint - Dyadic International, Inc. is undergoing a strategic shift to become a revenue-generating provider of ancillary recombinant protein products, with a focus on life sciences, nutrition, and industrial markets [1][2][3] Group 1: Leadership Changes - Joe Hazelton has been appointed as President, effective immediately, while continuing as Chief Operating Officer [1][6] - The leadership change aims to align the company’s focus on accelerating growth in the ancillary protein space [3][4] Group 2: Strategic Shift and Market Focus - Over the past 18 months, Dyadic has prioritized commercialization opportunities in high-growth segments such as cell culture media and non-animal food ingredients [2][8] - The company has achieved commercial validation through partnerships, including a collaboration with Proliant Health for recombinant human albumin and a joint venture with Fermbox Bio [2][4] Group 3: Operational and Strategic Goals - Joe Hazelton will oversee scaling scientific and commercial initiatives, deepening industry partnerships, and guiding corporate rebranding efforts [3][4] - The company’s C1 and Dapibus™ platforms are central to its strategy, enabling large-scale production of recombinant proteins for non-therapeutic applications [4][9] Group 4: Legacy Programs - While focusing on ancillary proteins, Dyadic will continue to develop its legacy biopharmaceutical programs under the oversight of Mark Emalfarb [5]